Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CureVac N.V. - Ordinary Shares (NQ:CVAC)

5.460 +0.010 (+0.18%)
Streaming Delayed Price Updated: 11:31 AM EDT, Aug 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CureVac N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates
Via ACCESS Newswire
BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth
BioNTech beat Q2 estimates with higher COVID vaccine revenue and reaffirmed 2025 guidance. 
Via Benzinga
Cooling US Bird Flu Wave Removes Tailwind For Moderna, Novavax, CureVac, Traws Pharma
The CDC reportedly deactivated its bird flu emergency response last week, folding surveillance into its regular flu tracking and ending animal infection updates. 
Via Stocktwits
This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday
 
Via Benzinga
Insights Ahead: CureVac's Quarterly Earnings
 
Via Benzinga
CureVac Announces Voting Results of General Meeting
Via ACCESS Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTLP, VERV, CVAC on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
5 Stocks To Ride The German Market Rally
 
Via Benzinga
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CVAC, KNW, SOAR, HLGN on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: CureVac N.V. (Nasdaq - CVAC), Know Labs, Inc. (NYSE American - KNW), Volato Group, Inc. (NYSE American - SOAR), Heliogen, Inc. (OTC - HLGN)
From Brodsky & Smith LLC
Via GlobeNewswire
This Sherwin-Williams Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday
 
Via Benzinga
Market Monitor News June 13 (Oracle UP - Gamestop DOWN)
U.S. stocks edge higher as inflation cools, Oracle soars on AI growth, and markets brace for Israel-Iran conflict escalation. 
Via Chartmill
Topics Artificial Intelligence Economy
Here are the top movers in Thursday's session.
Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Let's take a look at the stocks that are in motion in today's session.
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Nasdaq Moves Higher; Oracle Shares Jump After Upbeat Q4 Results
 
Via Benzinga
BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal
BioNTech agreed to buy CureVac for $1.25 billion, expanding its mRNA cancer research and boosting its oncology pipeline. 
Via Benzinga
CureVac, TELUS International, Oracle And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
There are notable gap-ups and gap-downs in today's session.
Let's have a look at what is happening on the US markets on Thursday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
BioNTech To Acquire CureVac In All-Stock Deal Valued At $1.25B: Retail Sees Breakthrough In Cancer Treatment
Under the terms of the deal, each CureVac share will be exchanged for approximately $5.46 in BioNTech American depositary shares. 
Via Stocktwits
CVAC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CureVac N.V. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Wondering what's happening in today's pre-market session?
Discover the top movers in Thursday's pre-market session and stay informed about market dynamics. 
Via Chartmill
Trump Administration Terminates $590 Million Moderna Bird Flu Vaccine Deal, Dismantling Biden-Era Pandemic Preparedness Effort
The Trump administration terminated a nearly $600 million award to Moderna for developing an mRNA-based bird flu vaccine, ending a key Biden-era pandemic preparedness initiative. The cancellation... 
Via Benzinga
Topics Government
CureVac (CVAC) Stock Rises After Q1 Update, Oncology Pipeline Gains Traction
CureVac stock surged after reporting Q1 2025 results and a positive pipeline update. The biotech firm narrowed its operating loss, and cash is expected to fund operations through 2028. 
Via Benzinga
CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates
Via ACCESS Newswire
CureVac Receives Additional Positive Validity Decision from European Patent Office in Ongoing Litigation Against BioNTech SE
Via ACCESS Newswire
CureVac Stock Declines On Weaker-Than-Expected Q4 Revenue: Retail’s On Wait-And-Watch Mode
The company reported revenue of €14.5 million for the fourth quarter, representing a decrease of €8.1 million from the corresponding period of 2023, and below an analyst estimate of €20.58, according... 
Via Stocktwits
Topics Government
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2024 and Provides Business Update
Via ACCESS Newswire
Earnings Scheduled For April 10, 2025
 
Via Benzinga
CureVac to Report Fourth Quarter and Full-Year 2024 Financial Results and Business Update on April 10, 2025
Via ACCESS Newswire
CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS